Listen to Gynecologic Oncology
This podcast covers the latest research and emerging topics in gynecologic oncology. It is a monthly series from the journal Gynecologic Oncology. Each episode features a conversation hosted by one of the journal's editors. The editor speaks with authors of the Editor's Choice article and the accompanying commentary.
Episodes
Do We Have the Courage? Pregnancy, Policy, and the Price Surgeons Pay
Editor's Choice: Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialtyEditorial: Pregnancy complications in gynecologic oncologists – A call to action to do betterHosted by: Paola Gehrig, MDUniversity of Virginia , Charlottesville, United States of AmericaFeaturing: Kelsey Goon, MDUniversity of Chicago, United States of
FIGO 2023 Upstaging: Overtreatment or Overdue Precision?
Editor's Choice: FIGO 2023 staging may result in overtreatment of early-stage endometrial cancerEditorial: A path to precision in endometrial cancer management: Moving past FIGO 2023Hosted by: David Gaffney, MD, PhDThe University of Utah, Salt Lake City, Utah, United States of AmericaFeaturing: Allison Roy, MDSUNY Upstate Medical University, Syracuse, NY, United States of AmericaJessica N. M
ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know
Editor's Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 updateEditorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelinesHosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USAFeaturing: Gregg Nelson, MD, PhD;
Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer
Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trialEditorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancerHosted by: Amanda Nickles F
Cologuard-like test for identification of endometrial cancer through vaginal sampling
Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleedingEditorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practiceHosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USAFeaturing: Jamie N. Bakkum-Gamez, MD; Department of Obstetr
PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial
Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery
Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancerEditorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selectionHosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta CanadaFeaturing: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, M
Recognizing and Managing ADC-Associated Pulmonary Toxicities
Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statementHosted by:Jose Alejandro Rauh-Hain, MD MPHDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAFeaturing:Charles A. Powell, MD, MBADivision of Pulmonary, Critical Care and Sleep Medicine, Tisch Can
In good SHAPE
Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trialEditorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stag
ctDNA-Guided PARPi Therapy in Ovarian Cancer
Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USAChristina
Beyond treatment: The who, why, when, where and what of cancer follow up
Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approachesEditorial: Who is following up? Rethinking survivorship and surveillanceHosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United StatesFeaturing:Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center,
Ovarian Cancer After Breast Cancer in Women with BRCA Variants
Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variantEditorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question?Hosted by:John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of AmericaFeaturing:Steven Narod, Women's College Resear
Making a difference: Molecules, mechanisms and more
Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancerEditor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerEditorial: From
Navigating Surgical Complexity After Ovarian Cancer Neoadjuvant Chemotherapy
Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAChiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAOliver Zivanovic,
Cervical Cancer Care in Focus: Consensus on Quality, Equity, and Radiation Therapy
Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.SEditorial: Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervica
Beyond Anesthesia: Self-Hypnosis in ERAS Programs
Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trialEditorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptomsHosted by:Jose Alejandro Rauh-Hain, MD, Associate Editor of Gynecologic OncologyFeaturing:Larissa Alejandra Meyer, Department of Gynecologic Oncology and Re
Carcinosarcoma Wars: A New Hope for TROP-2 Therapeutic Targeting
Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcomaEditorial: The search for new therapeutic options for uterine carcinosarcomaHosted by:Amanda Nickles Fader, MD, Deputy Editor of Gynecologic OncologyFeaturing:Britta Weigelt, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USASara Moufarrij, Gynecology Service
To divert or not to divert: that is the question
Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAsEditorial: Diverting ileostomy: An ounce of prevention, but when?Hosted by:Diane Yamada, MD, Deputy Editor of Gynecologic OncologyFeaturing:Anna Fagotti, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino
A randomized clinical trial of metformin in endometrial cancer
Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG studyEditorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equityHosted by:Sean Dowd
Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer
Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort studyEditorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?Hosted by:Warner Huh, MD, Deputy Editor of Gynecologic On
Prophylactic chemotherapy to prevent post-molar gestational trophoblastic disease - a long journey and a remarkable study
Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort studyEditorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special C
Clinical trials: Panacea or pitfall
Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survivalEditorial: Clinical trials are not the solution to inequities in cancer careHosted by:Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing:Ashley Felix, PhD, MPH, Associate Professor, Division of Epidemiology. The Ohio State University College of Public HealthDavid Sha
FOLR1 status: Landscape beyond high grade serous ovarian cancer
Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinomaEditorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinomaHosted by:Warner Huh, MD, Deputy Editor of Gynecologic OncologyFeaturing:Tullia Rushton, MDBeryl L. Manning-Geist, MDCheck out more content on the jour
Benefits of hormonal therapy for low grade serous ovarian cancer
Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective studyEditorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief!Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Alexa
Implementation and impact of a financial navigation program in gynecologic oncology
Editor’s Choice: Implementation of a financial navigation program in gynecologic oncologyEditorial: Financial toxicity: moving from describing the problem toward developing interventionsHosted by:Diane Yamada, MDFeaturing:Katharine M. Esselen, MDMargaret Liang, MDCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
LVSI in Stage 1 Endometrial Cancer
Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinomaEditorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?Hosted by:Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing:Mohamed Elshaikh, MDBeriwa
Primary Surgery versus Radiotherapy for Inguinal Lymph Nodes in Vulvar Cancer
Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulvaEditorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancerHosted by:Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic OncologyFeaturing:Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, CanadaDr Brenna Swi
2023 FIGO staging for endometrial cancer: a reappraisal on the path to continuous improvement
Editor's Choice: 2023 FIGO staging system for endometrial cancer: The evolution of the revolutionEditorial: 2023 FIGO staging for endometrial cancer, a look at both sides of the coinHosted by:Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology Featuring:Dr. Alexander Olawaiye, MD, University of Pittsburgh School of Medicine, USADr. David Gaffney, MD-PhD, University of Utah,
Shifting trends and sicker patients - the future of gynecologic cancer
Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologistsEditorial: Who you gonna call?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter HealthConnor C. Wang, MD, Northwestern University Feinberg School of MedicineEmm
SENTIREC-endo study: Is the juice worth the squeeze?
Editor’s Choice: Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo studyEditorial: Sentinel lymph node biopsy in high-risk endometrial cancer: The dénouementHosted by:Gregg Nelson, MD, Editor of Gynecologic OncologyFeaturing:Sarah M. Bjørnholt, MD, Aarhus University Hospital, DenmarkSean Dowdy, MD, Mayo Clinic, USACheck out mo
Caring for the Caregiver
Editor’s Choice: Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregiversEditorial: The importance of family-focused care in the setting of advanced gynecological cancersHosted by:Sean Dowdy, MD, Associate Editor of Gynecologic OncologyFeaturing:Rachel A. Pozzar, PhD, RN, Dana Farber Cancer Institute and Harvard Medical SchoolAllison J. Applebaum, PhD,
Lunchbox Trial
Editor’s Choice: Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinomaEditorial: What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial ca
Optimization of endometrial cancer survivorship through modification of lifestyle factors
Editor’s Choice: Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional studyEditorial: Optimising endometrial cancer survivorship through lifestyle changeHosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Ane Gerda Z. Eriksson, MD, Oslo University Hospital, Norway S. J. Kitso
Engagement with ERAS patients leads to improved outcomes
Editor’s Choice: Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patientsEditorial: How does mobile health engagement technology help gynecologic oncology patients recover from surgery, affect health equity, and impact healthcare costs?Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Teresa K.L. Boita
OS updates for Imagyn50
Editor’s Choice: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Scie
Is now the time to begin thromboprophylaxis for all patients with advanced ovarian cancer, including those undergoing neoadjuvant chemotherapy?
Editor’s Choice: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky
What is your center doing to improve genetic testing following abnormal MMR results in endometrial cancer?
Editor’s Choice: Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancerEditorial: Universal testing – Should it be that hard? Probably. If you're doing it rightHosted by:Gregg Nelson, MD, PhD, Editor of Gynecologic OncologyFeaturing:Bhavana Pothuri, MD, NYU Perlmutter Cancer CenterLeigha Senter, MS, CGC, The Ohio State University Colleg
The evolution of patient-centered endometrial cancer detection: testing tompon-based collection for methylated DNA markers
Editor’s Choice: Detection of endometrial cancer using tampon-based collection and methylated DNA markersEditorial: Early detection of endometrial cancerHosted by:Dineo Khabele, MD, Associate Editor of Gynecologic OncologyFeaturing:Jamie N. Bakkum-Gamez, MD, Mayo ClinicJonathan C. Dudley, MD, The Johns Hopkins University School of MedicineCheck out more content on the journal's homepage at h
TKI Toxicities: A Society of Gynecologic Oncology Podcast
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendationsHosted by:Róisín O’Cearbhaill, MD, Gynecologic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New YorkFeaturing:BJ Rimel, MD, Gynecologic Oncologist, Cedars-Sinai Medical CenterErin Crane, MD, MPH, Gynecologic Oncologist, Levine Cancer InstituteVicky Makker, MD, Medical Oncologist, Memori
ERAS Society Updates: What Every Gyn Oncologist Should Know
Editor’s Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 updateEditorial: Gynecologic oncology surgery – Ready for the next step in ERASHosted by:Amanda Nickles Fader, MD, Editor of Gynecologic OncologyFeaturing:Gregg Nelson, MD, PhD, University of CalgarySean Dowdy, MD, Mayo Clinic College of MedicineOlle Lj
Prioritizing and achieving diversity in clinical trial enrollment
Editor’s Choice: What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black womenEditorial: Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approachHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Ann Oluloro, MD, MPH, University of WashingtonEloise Chapman-Davis, MD, W
The times they are a changin’ – the future of the specialty
Editor’s Choice: Doubling down on the future of gynecologic oncology: The SGO future of the profession summit reportEditorial: “The times they are a-changin’” – And how are we managing?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Stephanie V. Blank, MD, Icahn School of Medicine at Mount SinaiWarner K. Huh, MD, FACOG, FACS, University of Alabama Birming
Intrathoracic Surgery and Ovarian Cancer Cytoreduction: Why the Chest Matters
Editor’s Choice: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center studyEditorial: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a “pelvic” surgeonHosted by:Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic OncologyFeaturing:Ryan M.
A Geo-Analyzer Tool that assessed insured patients in your metropolitan area with recurrent and metastatic cervix cancer
Editor’s Choice: Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancerEditorial: Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancerHosted by:Wendy R. Brewster, MD, PhD, Deputy Editor
Molecular Testing for Endometrial Cancer: A Society of Gynecologic Oncology Podcast
Molecular testing for endometrial cancer: An SGO clinical practice statementHosted by: Kari Hacker, MD, PhD, Gynecologic Oncologist, New York University Langone Health Featuring: Christine Walsh, MD, MS, Gynecologic Oncologist, University of ColoradoCarolyn McCourt, MD, Gynecologic Oncologist, Washington University School of MedicineKari Hacker, MD, PhD, is joined by Christine Walsh, MD, MS, and C
Sentinel lymph node mapping in endometrial complex atypical hyperplasia: good idea or have we gone too far?
Editor’s Choice: Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?Editor’s Choice: Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?Hosted by:Gregg Nelson, MD
Burnout and gynecologic oncology - does the problem still exist?
Article: SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncologyHosted by:Gregg Nelson, MD, PhD, Editor of Gynecologic OncologyFeaturing:Brittany A. Davidson, MD, Duke UniversityDavid M. Kushner, MD, UW School of Medicine and Public HealthCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
Exceptional PARP inhibitor responders: the good and the bad
Editor’s Choice: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaEditorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome dataHosted by: Ursula Matulonis, MD, Associate Edito
Management of primary low-grade serous ovarian carcinoma: are you up-to-date on the most contemporary prognostic factors and treatment strategies?
Editor’s Choice: Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survivalEditorial: Low grade serous ovarian cancer: Unpicking drivers of outcomeHosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic OncologyFeaturing:David M. Gershenson, MD, The University of Texas MD Anderson Cance
How do you manage the contralateral groin in early stage vulvar cancer with a unilateral positive sentinel lymph node?
Editor’s Choice: Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safeEditorial: When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?Hosted by: S. Diane Yamada, MD, Deputy Editor of Gynecologic OncologyFeaturing:Maaike Oonk, MD, U
Frailty assessment in gynecologic oncology - have you incorporated this into your practice?
Editor’s Choice: Preoperative assessment using the five-factor modified frailty index: A call for standardized preoperative assessment and prehabilitation services in gynecologic oncologyEditorial: Answering the call: Are we ready for action on frailty in gynecologic oncology?Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Mariam M. AlHilli, MD Gynecologic Onc
Complications after cytoreductive surgery and its impact on survival: where do we go from here?
Editor’s Choice: The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancerEditorial: Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstaclesHosted by:Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic OncologyFeaturing:Pr Alejandra Martinez, Institu
Immunotherapy Toxicities: A Society of Gynecologic Oncology Podcast
Editor’s Choice: Immunotherapy toxicities: An SGO clinical practice statementHosted by:Leslie Clark, MD, Gynecologic Oncologist, University of North Carolina in Chapel HillFeaturing:Róisín O’Cearbhaill, MD, Medical Oncologist, Memorial Sloan Kettering Cancer CenterRamez Eskander, MD, Gynecologic Oncologist, University of California San DiegoDr. Leslie Clark presents a patient case to frame a discu
Long-term cardiovascular complications among gynecologic cancer survivors
Editor’s Choice: Cardiovascular conditions and obesity among gynecologic cancer survivors: Results from the 2020 behavioral risk factor surveillance system surveyEditorial: The intersection of gynecologic cancer, obesity, and cardiovascular diseaseHosted by:Jose Alejandro Rauh-Hain, MD, MPH, Associate Editor of Gynecologic OncologyFeaturing:Steven S. Coughlin, MD, Augusta UniversityDaniel Addison,
Financial toxicity – the other side effect of cancer care
Editor’s Choice: Insurance-based disparities and risk of financial toxicity among patients undergoing gynecologic cancer operationsEditorial: Financial toxicity of surgical treatment for gynecological cancer: A growing malignancyHosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Joshua G. Cohen, MD, Gynecologic Oncologist, City of Hope Orange CountyFumiko Chi
Reducing non-surgical readmissions in gynecologic oncology
Editor’s Choice: Reducing non-surgical readmissions on a gynecologic oncology serviceEditorial: Our dual responsibility of improving quality and questioning the metrics: Reflections on 30-day readmission rate as a quality indicatorHosted by:John Farley, MD, Associate Editor of Gynecologic OncologyFeaturing:Catherine H. Watson, MD, Vanderbilt University Medical CenterLarissa Alejandra Meyer, MD MPH
Improving QOL for patients with cervical cancer: SLN biopsy
Editor’s Choice: SENTIREC – The sentinel node mapping in women with cervical cancer study – Patient-reported early lymphedema and its impact on quality of lifeEditorial: The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approachingHosted by:Sean C. Dowdy, MD, Associate Editor of Gynecologic OncologyFeaturing:Sara Elisabeth Sponholtz, MD, PhD, University of Southern
The ProMisE of molecular classification to standardize care in endometrial cancer
Editor’s Choice: Variation in practice in endometrial cancer and potential for improved care and equity through molecular classificationEditorial: The ProMisE of uniform care for endometrial cancer patientsHosted by:S. Diane Yamada, MD, Deputy Editor of Gynecologic OncologyFeaturing:Jessica N. McAlpine, MD, University of British ColumbiaG. Larry Maxwell, MD, FACOG, COL(ret) USA, Inova Health Syste
HRD: What does it really mean and are we looking at this the right way?
Editor’s Choice: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyEditorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?Hosted by: Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic OncologyFeaturing:Elizabeth Swishe
Optimizing Rural Ovarian Cancer Care
Editor’s Choice: Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patientsEditorial: Defining the essential role of the gynecologic oncologist in rural ovarian cancer care deliveryHosted by: David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Kristin Weeks, MD/PhD candidate, University of IowaDavid Shalowitz , MD, MSHP, Wake For
Recurrent Endometrial Cancer: A Society of Gynecologic Oncology Podcast
Hosted by: Floor Backes, MD, Gynecologic Oncologist, The Ohio State University Comprehensive Cancer CenterFeaturing:Vicky Makker, MD, Medical Oncologist, Memorial Sloan Kettering Cancer CenterMatthew Powell, MD, Gynecologic Oncologist and Chief, Division of Gynecologic Oncology, Washington University School of Medicine Siteman Cancer CenterAmanda Nickles Fader, MD, Gynecologic Oncologist and Profe
Looking Back at 2021: November Editor’s Choice
Editor’s Choice: Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancersEditorial: Next generation sequencing for gynecologic malignancy: Promise and potential pitfallsHosted by: Anil K. Sood, MD, MD Anderson Cancer CenterFeaturing:Tilley Jenkins Vogel, MD, Northshore University HealthSystemShannon N. Westin , MD, MPH, UT MD Anderson Cancer Cente
Differences in cervical cancer screening and follow-up for black and white women in the United States
Host: Barbara Goff; Deputy Editor, Gynecologic Oncology and Gynecologic Oncology ReportsFeaturing: Sabrina Ford & Sandra BrooksCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
March 2021: The Future Of Gynecologic Oncology: We are at a Crossroads
Host: David E. Cohn, MD, MBA, President, Society of Gynecologic Oncology,Deputy Editor Gynecologic OncologyGuest: Warner K. Huh, MD; Immediate Past-President,Society of Gynecologic OncologyCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
April 2020: Rare Tumors and Conditions
Rare Gynecologic Tumors: Coming of AgeHosted by: Dr. Laurel Rice, Associate EditorFeaturing: Dr. David Gershenson, Unveristy of TexasCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
2020 Virtual Annual SGO Meeting Report
The 2020 SGO Annual Meeting ReportHosted by: Dr. Warner Huh, Immediate Past President of SGOFeaturing: Dr. Kenneth Kim, Scientific Program Co-Chair, 2020 Virtual Annual SGO MeetingDr. Kathleen Moore, Scientific Program Co-Chair, 2020 Virtual Annual SGO MeetingCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
PARP Inhibitor Maintenance Therapy after Initial Chemotherapy for Advanced Ovary, Fallopian Tube and Primary Peritoneal Cancers
Hosted by: Dr. Deborah K. ArmstrongFeaturing: Dr. Eskander, Dr. O’Cearbhaill, Dr. PothuriLink: https://sgo.peachnewmedia.com/store/seminar/seminar.php?seminar=156603Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
Present and Future Impact of COVID-19 on the Practice and Delivery on Gynecologic Oncology Care
Basic Advice when dealing with COVID-19Hosted by: Warner K. Huh, MD, 2019-2020 SGO President, University of Alabama at BirminghamFeaturing: Elizabeth M. Swisher, MD, University of Washington (UW) Medicine, SeattleCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
Financial hardship among gynecologic cancer patients
Editor's Choice: Extensive financial hardship among gynecologic cancer patients starting a new line of therapyEditorial: Financial toxicity: An adverse effect worth of a black box warning?Hosted by: Dr. Beth Karlan, Editor-In-ChiefFeaturing: Dr. Karlan, Dr. Liang, Dr. Rauh-HainCheck out more content on the journal's homepage at https://www.gynecologiconcology-online.net
Does the transcriptome of ovarian neoplasms provide insight into its potential behavior?
Editor's Choice: Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signatureEditorial: Not All Peritoneal Implants Are Created EqualHosted by: Dr. David Cohn, Deputy EditorFeaturing: Dr. Cohn, Dr. Fauceglia, Dr. ShihCheck out more content on the journal's homepage at https://www.g
December 2019 Editor's Choice
Editor's Choice: A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyEditorial: Sunset, or dawn of a new age for ovarian cancer vaccine therapy?Hosted by: Dr. Barbara Goff,
Survival of endometrial cancer patients following lymphadenectomy or sentinel node procedure
Editor's Choice: Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithmEditorial: Enough already: Is this the end of comprehensive lymphadenectomy in endometrial cancer or are further trials needed?Hosted by: Dr. Stephen Rubin, Deputy EditorFeaturing: Dr. Rubin, Dr. Mariani, Dr. FaderChe
Inaugural Gynecologic Oncology Podcast - When to stop hCG surveillance following chemotherapy for gastational trophoblastic neoplasia
Editor's Choice: When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patientsEditorial: Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough?Hosted by: Dr. Beth Karlan, Editor-in-ChiefFeaturing: Dr. Berkowitz,
Recommended
Booked, Blonde & Busy w/ Olivia Ponton
McKinsey on Consumer and Retail
megahired.com
Hard Knocks Podcast
Effective Weight Loss for Moms | High protein, Strength Training, Lose Weight, Meal Planning, Fat Loss, Healthy Habits
The Human-Animal Connection - Pet Life Radio Original
Infinite Health with Dr. Arasi Maran
The Daily
World News Tonight with David Muir
The Joe Rogan Experience
English Vocabulary Help
TED Talks Daily
